Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Gene Variant Descriptions||ABL1 F359C lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359C has been identified as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 19798095, PMID: 26773037), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2022).|
|Associated Drug Resistance||Y|
|Category Variants Paths||
ABL1 mutant ABL1 F359C
|Transcript||gDNA||cDNA||Protein||Source Database||Genome Build|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04793399||Phase Ib/II||Atezolizumab + Bosutinib||Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients||Recruiting||ESP||0|
|NCT04160546||Phase II||Aspirin + Ponatinib||Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)||Recruiting||ESP||0|
|NCT03874858||Phase II||Nilotinib||A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib (DANTE)||Recruiting||ITA||0|